Get started
Author

Daehae Song

Observed institution: ABL Bio (South Korea)
ORCID: 0000-0003-4367-3793
Observed ORCID: 0000-0003-4367-3793
OpenAlex ID: A5028138201
Grabody B, an IGF1 receptor-based shuttle, mediates efficient delivery of biologics across the blood-brain barrier
2022 · Jung-Won Shin, Sungwon An, et al. · Cell Reports Methods · 34
PDF
A brain-shuttled antibody targeting alpha synuclein aggregates for the treatment of synucleinopathies
2025 · Sungwon An, John J. McInnis, et al. · npj Parkinson s Disease · 25
PDF
N-terminal selective conjugation method widens the therapeutic window of antibody–drug conjugates by improving tolerability and stability
2021 · Min Ji Ko, Daehae Song, et al. · mAbs · 13
PDF
Abstract 6524: A novel HER2/4-1BB bispecific antibody, YH32367 (ABL105) shows potent anti-tumor effect through tumor-directed T cell activation
2020 · Moo Young Song, Eun-Jung Lee, et al. · Cancer Research · 2
ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al. · Molecular Cancer Therapeutics · 1
Data from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure 3 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure S5 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Table S3 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Table S2 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure 5 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Table S4 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure 2 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure S6 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure 4 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure S16 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure S14 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure S2 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure 1 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure 6 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure S15 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure S3 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure S12 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Table S1 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure S13 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Works count: 33
Citation count: 75
H-index: 3
I10-index: 3
Year
Topic
Type